论文部分内容阅读
目的探讨瑞舒伐他汀对慢性肾病患者抗炎疗效。方法选取2009年11月-2010年12月90例慢性肾病患者,随机分为A、B两组,A组50例,给予瑞舒伐他汀钙10 mg/d;B组40例,给予阿托伐他汀钙10 mg/d,两组患者的年龄和性别相匹配。分别测定其治疗前及治疗后12周时血白细胞、高敏反应蛋白、纤维蛋白原、白介素-6、肿瘤坏死因子-α。结果两组治疗前各炎症指标水平差异无统计学意义(P>0.05)。与治疗前相比,两组患者治疗12周后炎症指标水平均较前明显下降(P<0.01),瑞舒伐他汀钙组比阿托伐他汀钙组炎症指标下降更为明显。结论瑞舒伐他汀可有效改善慢性肾病患者的炎症反应。
Objective To investigate the anti-inflammatory effect of rosuvastatin on patients with chronic kidney disease. Methods 90 patients with chronic kidney disease from November 2009 to December 2010 were randomly divided into A and B groups, 50 cases in group A received rosuvastatin calcium 10 mg / d, 40 cases in group B, Calcvastatin 10 mg / d, age and gender matched in both groups. The levels of leukocyte, hypersensitivity protein, fibrinogen, interleukin-6 and tumor necrosis factor-α were measured before treatment and 12 weeks after treatment respectively. Results There was no significant difference in the levels of each inflammation before treatment (P> 0.05). Compared with those before treatment, the levels of inflammatory markers in both groups were significantly decreased 12 weeks after treatment (P <0.01), while those in rosuvastatin calcium group were more significantly lower than those in atorvastatin calcium group. Conclusion Rosuvastatin can effectively improve the inflammatory response in patients with chronic kidney disease.